Sign up online today & collaborate
or click here to find out more
Clovis Oncology and Roche’s Genentech have entered into a clinical trials pact to investigate whether two of their cancer therapies work better in tandem than alone.
The companies have drawn up plans to test a novel combination of Genentech's investigational PDL1 inhibitor atezolizumab (MPDL3280A) and Clovis’ rociletinib in advanced EGFR-mutant non-small cell lung cancer (NSCLC).
For more click here